Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 7
2011 3
2014 1
2015 3
2016 1
2017 1
2018 2
2021 2
2022 2
2024 3
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
Familial Hodgkin's lymphoma from the perspective of HLA.
Sonmez M, Erkut N, Ucar F, Buruk K, Cobanoglu U, Bahce M, Ural AU. Sonmez M, et al. Among authors: erkut n. Intern Med. 2010;49(6):607-10. doi: 10.2169/internalmedicine.49.2873. Epub 2010 Mar 15. Intern Med. 2010. PMID: 20228601 Free article. Review.
Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology.
Baysal M, Aksoy E, Bedir KH, Özmen D, Patır P, Demirci U, Yaman S, Özdemir ZN, Gürsoy V, Yıldızhan E, Güven S, Çiftçiler R, İpek Y, Pınar İE, Genç EE, Mersin S, Uğur MC, Karabulut ZT, Hindilerden F, Hindilerden İY, Gulturk E, Cömert M, Karakuş V, Erkut N, Yıldız A, Ümit EG, Demir AM, Küçükkaya RD, Eşkazan AE. Baysal M, et al. Among authors: erkut n. J Thromb Thrombolysis. 2025 Feb;58(2):284-298. doi: 10.1007/s11239-024-03043-5. Epub 2024 Nov 11. J Thromb Thrombolysis. 2025. PMID: 39527392
Antifungal Prophylaxis and Treatment of Breakthrough Invasive Fungal Diseases in High-Risk Hematology Patients: A Prospective Observational Multicenter Study.
Metan G, Çiftçioğlu A, Saba R, Kılıç AU, Özdemir K, Çağ Y, Ünal DK, Aksoy F, Berk H, Mert G, Tunçcan ÖG, Tombak A, Balkan İİ, Çavuş SA, Kandemir B, Mutlu B, İnkaya AÇ, Kaynar L, Atay MH, Dursun FE, Saydam G, Ünsal Y, Sarı SF, Akan H; Study group. Metan G, et al. Indian J Hematol Blood Transfus. 2025 Jan;41(1):75-88. doi: 10.1007/s12288-024-01790-2. Epub 2024 May 20. Indian J Hematol Blood Transfus. 2025. PMID: 39917507
Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.
Saydam G, Unal A, Haznedaroglu IC, Hacihanifioglu A, Mehtap O, Kurtoglu E, Gocer M, Turgut M, Kelkitli E, Atay MH, Guler N, Koluman BU, Sonmez M, Erkut N, Kaya E, Kuku I, Erkurt MA, Ozet G, Ceran F, Sahin F, Soyer N, Nalcaci M, Yilmaz M, Bozkurt S, Aver B, Ozdengulsun B, Ozbilgili E, Ilhan O. Saydam G, et al. Among authors: erkut n. Int J Hematol Oncol. 2022 Jun 30;11(3):IJH40. doi: 10.2217/ijh-2021-0008. eCollection 2022 Jun. Int J Hematol Oncol. 2022. PMID: 36101779 Free PMC article.
28 results